Canopy Growth (CGC) Accumulated Expenses (2019 - 2026)
Canopy Growth (CGC) reported Accumulated Expenses of $11.4 million for Q1 2026, up 19.36% on a YoY basis from $9.6 million in Q1 2025, and up 25.54% sequentially from $9.1 million in Q4 2025.
Canopy Growth (CGC) Accumulated Expenses (2019 - 2026) Analysis & Trends
Canopy Growth (CGC) has 8 years of Accumulated Expenses data on file, last reported at $11.4 million in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 19.36% year-over-year to $11.4 million; the trailing twelve-month figure through Mar 2026 stood at $11.4 million (up 19.36% YoY), and the FY2026 full-year result was $11.4 million, up 19.36% from the prior year.
- Accumulated Expenses climbed to $11.4 million in Q1 2026, from $9.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $59.4 million in Q1 2022 to a low of $7.7 million in Q4 2024.
- A 5-year average of $23.9 million and a median of $15.8 million in 2024 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses jumped 275.56% in 2023 and tumbled 77.31% in 2024, its largest moves.
- Tracing CGC's Accumulated Expenses over 5 years: stood at $21.5 million in 2022, then tumbled by 41.48% to $12.6 million in 2023, then sank by 38.49% to $7.7 million in 2024, then grew by 17.43% to $9.1 million in 2025, then climbed by 25.54% to $11.4 million in 2026.
- Business Quant data shows CGC's Accumulated Expenses at $11.4 million in Q1 2026, $9.1 million in Q4 2025, and $28.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.42 Mn |
| Dec 31, 2025 | 9.10 Mn |
| Sep 30, 2025 | 28.65 Mn |
| Jun 30, 2025 | 11.74 Mn |
| Mar 31, 2025 | 9.57 Mn |
| Dec 31, 2024 | 7.75 Mn |
| Sep 30, 2024 | 8.75 Mn |
| Jun 30, 2024 | 15.83 Mn |
| Mar 31, 2024 | 40.10 Mn |
| Dec 31, 2023 | 12.60 Mn |
| Sep 30, 2023 | 38.54 Mn |
| Jun 30, 2023 | 56.15 Mn |
| Mar 31, 2023 | 39.75 Mn |
| Dec 31, 2022 | 21.52 Mn |
| Sep 30, 2022 | 20.14 Mn |
| Jun 30, 2022 | 14.95 Mn |
| Mar 31, 2022 | 59.43 Mn |
| Dec 31, 2021 | 17.90 Mn |
| Sep 30, 2021 | 68.38 Mn |
| Jun 30, 2021 | 29.34 Mn |